ANIK Q3 2025 Earnings — Anika Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ANIKAnika Therapeutics, Inc.

$213M

Q3 2025 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$28M-28.2% YoY

Gross Profit

$16M56.0% margin

Operating Income

-$3M-11.6% margin

Net Income

-$2M-8.4% margin

EPS (Diluted)

$-0.16

QoQ Revenue Growth

-1.4%

Cash Flow

Operating Cash Flow

$7M

Free Cash Flow

$5M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$189M

Total Liabilities

$43M

Stockholders' Equity

$147M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$28M	$39M	-28.2%
Gross Profit	$16M	$1M	+982.2%
Operating Income	-$3M	-$28M	+88.5%
Net Income	-$2M	-$30M	+92.2%

Geographic Segments

UNITED STATES

$17M75%

Europe

$6M25%